Competing endogenous RNA network crosstalk reveals novel molecular markers in colorectal cancer. Issue 8 (8th May 2018)

• Record Type: Journal Article
• Authors: Samir, Nehal; Matboli, Marwa; El‐Tayeb, Hanaa; El‐Tawdi, Ahmed; Hassan, Mohmed K.; Waly, Amr; EL‐Akkad, Hesham A. E.; Ramadan, Mohamed G.; Al‐Belkini, Tarek N.; El‐Khamisy, Sherif; El‐Asmar, Farid
• Is Part Of: Journal of cellular biochemistry. Volume 119:Issue 8(2018)
• Page Start: 6869
• Page End: 6881
• Publication Date: 2018-05-08
• Subjects: bioinformatics -- colorectal cancer -- competing endogenous RNA -- diagnosis; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.26884
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: The competing endogenous RNA networks play a pivotal role in cancer diagnosis and progression. Novel properstrategies for early detection of colorectal cancer (CRC) are strongly needed. We investigated a novel CRC‐specific RNA‐based integrated competing endogenous network composed of lethal3 malignant brain tumor like1 (L3MBTL1) gene, long non‐coding intergenic RNA‐ ( lncRNA RP11‐909B2.1 ) and homo sapiens microRNA‐595 (hsa‐ miRNA‐595 ) using in silico data analysis. RT‐qPCR‐based validation of the network was achieved in serum of 70 patients with CRC, 40 patients with benign colorectal neoplasm, and 20 healthy controls. Moreover, in cancer tissues of 20 of the 70 CRC cases were involved in the study. The expression of RNA‐based biomarker network in both CRC and adjacent non‐tumor tissues and their correlation with the serum levels of this network members was investigated. Lastly, the expression levels of the chosen ceRNA was verified in CRC cell line. Our results revealed that the three RNAs‐based biomarker network (long non‐coding intergenic RNA‐[ lncRNA RP11‐909B2.1 ], Homo sapiens microRNA‐595 [hsa‐ miRNA‐595 ], and L3MBTL1 mRNA ), had high sensitivity and specificity for discriminating CRC from healthy controls and also from benign colorectal neoplasm. The data suggest that among these three RNAs, serum lncRNA RP11‐909B2.1 could be a promising independent prognostic factors in CRC. The circulatory RNA based biomarker panel can act as potential biomarker for CRC diagnosis and prognosis. Key points: The circulating transcriptome has been revealed as a novel class of non‐invasive biomarker with high specificity and stability for early detection of CRC. We proposed an integrative approach between differential L3MBTL1 gene expression with the selected epigenetic regulators. This approach has generated an interesting biomarker panel (lncRNA RP11‐909B2.1, hsa‐miRNA‐595, and L3MBTL1 mRNA))for CRC diagnosis and prognosis. To the best of our knowledge, it is the first study to the expression of lncRNA RP11‐909B2.1, hsa‐miRNA‐595, and L3MBTL1 mRNA as a competing endogenous network in sera of CRC patients in comparison to benign colonic leision and healthy control individuals.